Generic Zorvolex Availability
Last updated on Apr 10, 2025.
Zorvolex is a brand name of diclofenac, approved by the FDA in the following formulation(s):
ZORVOLEX (diclofenac - capsule;oral)
-
Manufacturer: ZYLA
Approval date: October 18, 2013
Strength(s): 18MG (discontinued) [RLD], 35MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zorvolex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Formulation of diclofenac
Patent 8,679,544
Issued: March 25, 2014
Inventor(s): Dodd Aaron & Meiser Felix & Norret Marck & Russell Adrian & Bosch H William
Assignee(s): iCeutica Pty Ltd.The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
Patent expiration dates:
- April 23, 2030✓
- April 23, 2030
-
Formulation of diclofenac
Patent 8,999,387
Issued: April 7, 2015
Inventor(s): Dodd Aaron & Meiser Felix & Norret Marck & Russell Adrian & Bosch H William
Assignee(s): iCeutica Pty Ltd.The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
Patent expiration dates:
- April 23, 2030✓
- April 23, 2030
-
Formulation of diclofenac
Patent 9,017,721
Issued: April 28, 2015
Inventor(s): Dodd Aaron & Meiser Felix & Norret Marck & Russell Adrian & Bosch H William
Assignee(s): iCeutica Pty Ltd.The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
Patent expiration dates:
- April 23, 2030✓
- April 23, 2030
-
Formulation of diclofenac
Patent 9,173,854
Issued: November 3, 2015
Inventor(s): Dodd Aaron & Meiser Felix & Norret Marck & Russell Adrian & Bosch H William
Assignee(s): iCeutica Pty Ltd.The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
Patent expiration dates:
- April 23, 2030✓
- April 23, 2030
-
Formulation of diclofenac
Patent 9,180,095
Issued: November 10, 2015
Inventor(s): Dodd Aaron & Meiser Felix & Norret Marck & Russell Adrian & Bosch H William
Assignee(s): iCeutica Pty Ltd.The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
Patent expiration dates:
- April 23, 2030✓
- April 23, 2030
-
Formulation of diclofenac
Patent 9,180,096
Issued: November 10, 2015
Inventor(s): Dodd Aaron & Meiser Felix & Norret Marck & Russell Adrian & Bosch H William
Assignee(s): iCeutica Pty Ltd.The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
Patent expiration dates:
- April 23, 2030✓
- April 23, 2030
-
Formulation of diclofenac
Patent 9,186,328
Issued: November 17, 2015
Inventor(s): Dodd Aaron & Meiser Felix & Norret Marck & Russell Adrian & Bosch H William
Assignee(s): iCeutica Pty Ltd.The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
Patent expiration dates:
- April 23, 2030✓
- April 23, 2030
More about Zorvolex (diclofenac)
- Zorvolex consumer information
- Check interactions
- Compare alternatives
- Reviews (22)
- Drug images
- Latest FDA alerts (11)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: Nonsteroidal anti-inflammatory drugs
- Breastfeeding
- En español
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.